F-18 fluorodeoxyglucose uptake in leiomyomatous uterus

International Journal of Gynecological Cancer

Volumn 17, Issue 1, 2007, Pages 285-290

  Shida, M ^a   Murakami, M ^a,c   Tsukada, H ^a   Ishiguro, Y ^a   Kikuchi, K ^a   Yamashita, E ^a   Kajiwara, H ^a   Yasuda, M ^a   Ide, M ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HIMEDIC Imaging Center at Lake Yamanaka   (Japan)

^c TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

Author keywords

FDG PET; Uterine leiomyoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ANEMIA; ARTICLE; CASE REPORT; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; GENITAL BLEEDING; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; UTERUS MYOMA;

FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LEIOMYOMA; MIDDLE AGED; RADIOPHARMACEUTICALS; UTERINE NEOPLASMS;

EID: 33846837553     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00778.x     Document Type: Article

References (22)

1. Lefebvre G, Vilos G, Allaire C et al. The management of uterine leiomyomas. J Obstet Gynaecol Can 2003;25:396-405.
2. Schelbert HR, Hoh CK, Roral HD et al. Procedure guideline for tumor imaging using Fluorine-18-FDG. J Nucl Med 1998;39:1302-5.
3. Yasuda S, Ide M, Fujii H et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000;83:1607- 11.
4. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 2004;45:82s-95s.
5. Kim EK. Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology. Int J Gynecol Cancer 2004;14:12-4.
6. Nakamoto Y, Saga T, Fujii S. Positron emission tomography application for gynecologic tumors. Int J Gynecol Cancer 2005;15:701-9.
7. Pandit-Taskar N. Oncologic imaging in gynecologic malignancies. J Nucl Med 2005;46:1842-50.
8. Murakami M, Miyamoto T, Iida T et al. Whole-body positron emission tomography and tumor marker CA 125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 2006;16(Suppl. 1):99-107.
9. Murakami M, Tsukada H, Shida H et al. Whole-body positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET) for detection of recurrence in uterine sarcomas. Int J Gynecol Cancer 2006;16:854-60.
10. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986;76:399-420.
11. Major FJ, Blessing JA, Silberberg SG et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993;71:1701-9.
12. Jadvar H, Fischman AJ. Evaluation of rare tumors with fluorodeoxyglucose positron emission tomography. Clin Positron Imaging 1999;2:153-8.
13. Umesaki N, Tanaka T, Miyama M et al. Positron emission tomography with 18F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001;80:372-7.
14. Lerman H, Metser U, Grisaru D et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004;45:266-71.
15. 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging 2005;32:549-56.
16. Koyama K, Okamura T, Kawabe J et al. Evaluation 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 2003;44:353-8.
17. Kubota K, Itoh M, Ozaki K et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001;28:696- 703.
18. Lee WL, Liu RS, Yuan CC et al. Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: preliminary findings on positron emission tomography. Fertil Steril 2001;75:638-9.
19. Kao CH. FDG uptake in a huge uterine myoma. Clin Nucl Med 2003;28:249.
20. Ak I, Ozalp S, Yalcin OT et al. Uptake of 2-[18F]fluoro-2-deoxy-D- glucose in uterine leiomyoma: imaging of four patients by coincidence positron emission tomography. Nucl Med Commun 2004;25:941-5.
21. Higashi H, Saga T, Nakamoto Y et al. Relation between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transpoter-1 expression in pancreatic cancer. J Nucl Med 2002;43:173-80.
22. Kurokawa T, Yoshida Y, Kawahara K et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004;109:926-32.